{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:12Z","timestamp":1793140692642,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.expneurol.2007.07.021","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T11:15:09Z","timestamp":1187867709000},"page":"110-119","source":"Crossref","is-referenced-by-count":173,"title":["Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors"],"prefix":"10.1016","volume":"208","author":[{"given":"Maria Grazia","family":"Morgese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2007.07.021_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0006-8993(95)00645-7","article-title":"The cannabinoid agonist WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway","volume":"691","author":"Anderson","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2007.07.021_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2004.11.005","article-title":"Evidence for novel cannabinoid receptors","volume":"106","author":"Begg","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2007.07.021_bib3","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1523\/JNEUROSCI.20-09-03401.2000","article-title":"Reversal of dopamine D2-receptor responses by an anandamide transport inhibitor","volume":"20","author":"Beltramo","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2007.07.021_bib5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/j.1471-4159.2006.03696.x","article-title":"Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats","volume":"96","author":"Carta","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2007.07.021_bib6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2007.07.021_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2007.07.021_bib8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.neuroscience.2006.02.074","article-title":"Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain","volume":"139","author":"Cristino","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2007.07.021_bib10","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fernandez","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2007.07.021_bib11","doi-asserted-by":"crossref","first-page":"12856","DOI":"10.1074\/jbc.M008555200","article-title":"The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism","volume":"276","author":"De Petrocellis","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2007.07.021_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fj.14.10.1432","article-title":"Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease","volume":"14","author":"Di Marzo","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2007.07.021_bib14","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib15","first-page":"S9","article-title":"The spectrum of levodopa-induced dyskinesias","volume":"47","author":"Fahn","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.104.078980","article-title":"Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3\u2032-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation","volume":"313","author":"Fegley","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2007.07.021_bib17","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1460-9568.2003.02896.x","article-title":"Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskenesias","volume":"18","author":"Ferrer","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/mol.105.016667","article-title":"Loss of synaptic D1 dopamine\/N-methyl-d-aspartate glutamate receptor complexes in l-DOPA-induced dyskinesia in the rat","volume":"69","author":"Fiorentini","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib19","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/7268","article-title":"Dopamine activation of endogenous cannabinoid signaling in dorsal striatum","volume":"2","author":"Giuffrida","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib21","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.prostaglandins.2006.08.002","article-title":"Quantification of endocannabinoids in rat biological samples by GC\/MS: technical and theoretical considerations","volume":"81","author":"Hardison","year":"2006","journal-title":"Prostaglandins Lip. Med."},{"key":"10.1016\/j.expneurol.2007.07.021_bib23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s000180300052","article-title":"Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response","volume":"60","author":"Hermann","year":"2003","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"1","author":"Kathuria","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2007.07.021_bib26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1523\/JNEUROSCI.4166-04.2005","article-title":"Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro","volume":"25","author":"Kim","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1054\/plef.2001.0359","article-title":"Oxidative metabolism of endocannabinoids","volume":"66","author":"Kozak","year":"2002","journal-title":"Prostaglandins, Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.expneurol.2007.07.021_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","article-title":"Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models","volume":"445","author":"Kreitzer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2007.07.021_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.expneurol.2005.06.006","article-title":"Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?","volume":"197","author":"Lane","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","article-title":"Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease","volume":"84","author":"Lastres-Becker","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2007.07.021_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuropharm.2006.04.016","article-title":"A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and l-DOPA induced locomotion in normal and reserpine-treated rats","volume":"51","author":"Lee","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2007.07.021_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2007.07.021_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","author":"Mackie","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.expneurol.2005.11.002","article-title":"Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?","volume":"197","author":"Marin","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib36","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1523\/JNEUROSCI.23-08-03136.2003","article-title":"Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors","volume":"23","author":"Marinelli","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nbd.2006.01.009","article-title":"Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine","volume":"22","author":"Meissner","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2007.07.021_bib38","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1073\/pnas.060496197","article-title":"Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human","volume":"97","author":"Mezey","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib39","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archneur.1992.00530350037016","article-title":"Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on\u2013off phenomenon","volume":"49","author":"Nutt","year":"1992","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib40","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.62.1_suppl_1.S17","article-title":"The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits","volume":"62","author":"Obeso","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2007.07.021_bib41","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.0603861103","article-title":"The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin","volume":"103","author":"Patwardhan","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib42","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.expneurol.2007.07.021_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0165-6147(00)01482-6","article-title":"The endocannabinoid system as a target for therapeutic drugs","volume":"21","author":"Piomelli","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2003.09.001","article-title":"Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia","volume":"185","author":"Ravenscroft","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib46","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/0024-3205(95)00186-A","article-title":"The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: role of nigrostriatal dopaminergic neurons","volume":"56","author":"Romero","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib47","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2007.07.021_bib48","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1124\/jpet.301.3.900","article-title":"Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide","volume":"301","author":"Ross","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2007.07.021_bib49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0006-8993(94)91533-4","article-title":"Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat","volume":"633","author":"Sakai","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2007.07.021_bib50","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2007.07.021_bib51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0166-2236(00)01630-1","article-title":"New perspectives on enigmatic vanilloid receptors","volume":"23","author":"Szallasi","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0165-6147(99)01436-4","article-title":"Are cannabinoids endogenous ligands for the VR1 capsaicin receptor","volume":"21","author":"Szolcsanyi","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molbrainres.2004.12.003","article-title":"Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain","volume":"135","author":"Toth","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.expneurol.2007.07.021_bib54","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.biopsych.2005.08.019","article-title":"Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications","volume":"59","author":"Tzavara","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2007.07.021_bib55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2007.07.021_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s100720170066","article-title":"Unawareness of dyskinesias in Parkinson's and Huntington's diseases","volume":"22","author":"Vitale","year":"2001","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib57","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1523\/JNEUROSCI.0944-06.2006","article-title":"Endothelial proliferation and increased blood\u2013brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia","volume":"26","author":"Westin","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2007.07.021_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0165-6147(99)01430-3","article-title":"Anandamide \u2013 the other side of the coin","volume":"21","author":"Zygmunt","year":"2000","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488607002993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488607002993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T02:46:42Z","timestamp":1587869202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488607002993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0014488607002993"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2007.07.021","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}